Roche Ends Deal with Ligand

Xconomy San Diego — 

San Diego’s Ligand Pharmaceuticals (NASDAQ: LGNDD) said today that Roche has terminated their collaboration and licensing agreement to develop a treatment for hepatitis C, according to a regulatory filing. Ligand and the Swiss pharmaceutical giant signed the drug development deal two years ago, and Roche made a $6.5 million milestone payment to Roche in April.